Literature DB >> 8429432

Interference of immune globulin with measles and rubella immunization.

G R Siber1, B G Werner, N A Halsey, R Reid, J Almeido-Hill, S C Garrett, C Thompson, M Santosham.   

Abstract

Passively acquired antibody may interfere with the active antibody response to live viral vaccines such as measles and rubella. To evaluate the duration of this inhibitory effect, we measured the measles and rubella antibody responses of Apache children immunized with measles, mumps, and rubella vaccine at varying intervals after administration of an immune globulin termed bacterial polysaccharide immune globulin (BPIG). This specific immune globulin contained measles and rubella antibody titers similar to those in standard intramuscularly and intravenously administered immune globulins. Antibody responses to measles vaccine were inhibited for up to 5 months after a BPIG dose of 80 mg IgG per kilogram of body weight, but responses to rubella vaccine were inhibited for only 2 months. Most children who had a decreased measles antibody response to primary measles, mumps, and rubella immunization given 1 1/2 to 4 months after BPIG administration responded to a booster immunization given 6 months after their last BPIG dose. We conclude that high doses of immune globulin (> 10 mg/kg) may inhibit the antibody response to measles for more than 3 months. We propose that the interval between administration of immune globulin and measles and rubella immunization be adjusted on the basis of the dose of immune globulin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8429432     DOI: 10.1016/s0022-3476(06)80114-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  11 in total

1.  Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research.

Authors:  P A Brogan; A Bose; D Burgner; D Shingadia; R Tulloh; C Michie; N Klein; R Booy; M Levin; M J Dillon
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

2.  Characterization of a potent and highly unusual minimally enhancing antibody directed against dengue virus.

Authors:  Max Renner; Aleksandra Flanagan; Wanwisa Dejnirattisai; Chunya Puttikhunt; Watchara Kasinrerk; Piyada Supasa; Wiyada Wongwiwat; Kriangkrai Chawansuntati; Thaneeya Duangchinda; Alison Cowper; Claire M Midgley; Prida Malasit; Juha T Huiskonen; Juthathip Mongkolsapaya; Gavin R Screaton; Jonathan M Grimes
Journal:  Nat Immunol       Date:  2018-10-15       Impact factor: 25.606

3.  Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.

Authors:  Luke N Robinson; Kannan Tharakaraman; Kirk J Rowley; Vivian V Costa; Kuan Rong Chan; Yee Hwa Wong; Li Ching Ong; Hwee Cheng Tan; Tyree Koch; David Cain; Rama Kirloskar; Karthik Viswanathan; Chong Wai Liew; Hamid Tissire; Boopathy Ramakrishnan; James R Myette; Gregory J Babcock; V Sasisekharan; Sylvie Alonso; Jianzhu Chen; Julien Lescar; Zachary Shriver; Eng Eong Ooi; Ram Sasisekharan
Journal:  Cell       Date:  2015-07-16       Impact factor: 41.582

Review 4.  Active immunization in the United States: developments over the past decade.

Authors:  P H Dennehy
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 5.  Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity.

Authors:  Jessica R Durkee-Shock; Michael D Keller
Journal:  Ann Allergy Asthma Immunol       Date:  2022-06-16       Impact factor: 6.248

6.  Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin.

Authors:  Masaru Miura; Yasuki Katada; Jun Ishihara
Journal:  Eur J Pediatr       Date:  2003-11-18       Impact factor: 3.183

7.  A Comprehensive Update on Kawasaki Disease Vasculitis and Myocarditis.

Authors:  Priya R Soni; Magali Noval Rivas; Moshe Arditi
Journal:  Curr Rheumatol Rep       Date:  2020-02-05       Impact factor: 4.686

8.  Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy.

Authors:  Stacey Schultz-Cherry; Maureen A McGargill; Paul G Thomas; Jeremie H Estepp; Aditya H Gaur; E Kaitlynn Allen; Kim J Allison; Li Tang; Richard J Webby; Sean D Cherry; Chun-Yang Lin; Thomas Fabrizio; Elaine I Tuomanen; Joshua Wolf
Journal:  Open Forum Infect Dis       Date:  2021-08-10       Impact factor: 3.835

9.  Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients.

Authors:  Maddalena Casale; Nicoletta Di Maio; Valentina Verde; Saverio Scianguetta; Maria Grazia Di Girolamo; Rita Tomeo; Domenico Roberti; Saverio Misso; Silverio Perrotta
Journal:  Vaccines (Basel)       Date:  2021-05-27

10. 

Authors:  Hans-Jürgen Laws; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Maximilian Christopeit; Jane Hecht; Ulrich Heininger; Inken Hilgendorf; Winfried Kern; Kerstin Kling; Guido Kobbe; Wiebe Külper; Thomas Lehrnbecher; Roland Meisel; Arne Simon; Andrew Ullmann; Maike de Wit; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-05       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.